Organ Damage and Quality of Life in Antiphospholipid Syndrome

被引：0
作者：
P. Alba
J. A. Gómez-Puerta
M. V. Goycochea-Robles
M. C. Amigo
机构：
[1] Universidad Nacional de Córdoba,Hospital Córdoba, Cátedra de Medicina I UHMI n 3
[2] Universidad de Antioquia,Grupo de Inmunología Celular e Inmunogenética (GICIG)
[3] Universidad Nacional Autónoma de México,Unidad de Investigación en Epidemiología Clínica, Hospital General Regional No. 1, IMSS
[4] Universidad Nacional Autónoma de México,Centro Médico ABC
来源：
Current Rheumatology Reports | 2016年 / 18卷
关键词：
Systemic autoimmune diseases (SAD); Organ damage; Quality of life; Health-related quality of life (HRQoL); Antiphospholipid syndrome (APS); Damage index in APS (DIAPS); SLICC/ACR Damage Index (SDI);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Antiphospholipid syndrome (APS) affects young patients in the most productive years of their life, and the consequences of organic or tissue damage involve a decrease in health-related quality of life (HRQoL). While acute disease manifestations of APS are well known, information on the long-term prognosis and damage in affected patients is still very limited. Systemic lupus erythematosus (SLE) patients would be expected to experience long-term complications and even die as a consequence of APS. Organ damage in APS has been evaluated using different methods and definitions, including the SLICC/ACR Damage Index (SDI), which tend to underestimate aPL-related damage. A new damage index in APS has been proposed (DIAPS), and it seems to be more accurate than SDI. Given the implications for morbidity and mortality, it is imperative to assess accurately aPL-related damage and HRQoL in patients with APS.
引用
收藏
相关论文
共 210 条
[1]  
Strand V(2000)Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology Lupus 9 322-7
[2]  
Gladman D(2008)Connective tissue diseases: evaluation of clinical response Rheumatology (Oxford) 47 234-5
[3]  
Isenberg D(2006)International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 4 295-306
[4]  
Petri M(2015)Antiphospholipid syndrome: an update Eur J Clin Invest 45 653-62
[5]  
Smolen J(2014)What do we know about the cardiac valve lesion in the antiphospholipid syndrome (APS)? Lupus 23 1259-61
[6]  
Tugwell P(1992)Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients Ann Intern Med 117 303-8
[7]  
Fischer-Betz R(1992)The catastrophic antiphospholipid syndrome J Rheumatol 19 508-12
[8]  
Schneider M(2015)Antiphospholipid syndrome BMJ 350 h1426-13
[9]  
Miyakis S(1997)The reliability of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index in patients with systemic lupus erythematosus Arthritis Rheum 40 809-6
[10]  
Lockshin MD(2000)The Systemic Lupus International Collaborating Clinics/ American College of Rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison J Rheumatol 27 373-6
12345678910